Relationship between β-adrenergic receptor genetic polymorphism and disease susceptibility as well as differences in drug response

Abstract

CLC Number:

R969

LIU Jie, LIU Zhao-qian, ZHOU Hong-hao. Relationship between β-adrenergic receptor genetic polymorphism and disease susceptibility as well as differences in drug response[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(6): 601-608.

References

1 Johnson M.The beta-adrenoceptor[J]. Am J Respir Crit Care Med, 1998;158:S146-S153.
2 Davare MA, Avdonin V, Hall DD, et al. A β₂-adrenergic receptor signaling complex assembled with the Ca²⁺ channel Cav1. 2[J]. Science, 2001;293: 98-101.
3 Strosberg AD.Structure and function of the β₃-adrenergic receptor[J]. Annu Rev Pharmacol Toxicol, 1997;37: 421-450.
4 Strader CD, Fong TM, Tota MR, et al. Structure and function of G protein-coupled receptors[J]. Annu Rev Biochem, 1994; 63:101-132.
5 Emorine LJ, Marullo S, Briend-Sutren MM, et al. Molecular characterization of the human β₃-adrenergic receptor[J]. Science, 1989; 245: 1118-1121.
6 Emorine LJ, Marullo S, Delavier-Klutchko C, et al. Structure of the gene for human β₂-adrenergic receptor: expression and promoter characterization[J]. Proc Natl Acad Sci USA, 1987; 84:6995-6999.
7 Frielle T, Collins S, Daniel KW, et al. Cloning of the cDNA for the human β₁-adrenergic receptor[J]. Proc Natl Acad Sci USA, 1987;84: 7920-7924.
8 Frielle T, Caron MG, Lefkowitz RJ. Properties of the beta 1-and beta 2-adrenergic receptor subtypes revealed by molecular cloning[J]. Clin Chem, 1989; 35:721-725.
9 CaulfieldMJ. Genes for common disease[J]. Br J Clin Pharmacol, 2001; 51:1-3.
10 Collins S, Ostrowski J, Lefkowitz RJ.Cloning and sequence analysis of the human β₁-adrenergic receptor 5-flanking promoter region[J]. Biochim Biophy si Acta, 1993;1172: 171-174.
11 Maqbool A, Hall AS, Ball SG, et al. Common polymorphisms of β₁-adrenoceptor: identification and rapid screening assay[J]. Lancet, 1999;353:897.
12 Mason DA, Moore JD, Green SA, et al. A gain-of-function polymorphism in a G-protein coupling domain of the human β₁-adrenergic receptor[J]. J Biol Chem, 1999;274: 12670-12674.
13 Moore JD, Mason DA, Green SA, et al. Racial difference in the frequencies of cardiac β₁-adrenergic receptor polymorphisms: analy sis of c145A→G and c1165G→C[J]. Hum Mutat, 1999;14: 271.
14 Pidlowski S, Wenzel K, Luther HP, et al. β₁-adrenoceptor gene variations:a role in idiopathic dilated cardiomyopathy[J] ? J MolMed, 2000;78:87-93.
15 Liu ZQ, Liu J, Xiang ZH, et al. Distributive characteristics of Ser49Gly and Gly389Arg genetic polymorphisms of beta1-adrenoceptor in Chinese Han and Dai populations[J]. Acta Pharmacol Sin, 2006;27: 254-258.
16 Tesson F, Charron P, Peuchmaurd M, et al. Characterization of a unique genetic variant in the β₁-adrenoceptor gene and evaluation of its role in idiopathic dilated cardiomyopathy[J]. J Mol Cell Cardiol, 1999;31: 1025-1032.
17 Frielle T, KobilK_a B, Lefkowitz RJ, et al. Human β₁-and β₂-adrenergic receptors:structurally and functionally related receptors derived from distinct genes[J]. Trends Neurosci, 1988; 11: 321-324.
18 Rathz DA, Brown KM, Kramer LA, et al. Amino acid 49 polymorphisms of the human β₁-adrenergic receptor affect agonist-promoted trafficking[J]. J Cardiovasc Pharmacol, 2002; 39: 155-160.
19 Borjesson M, Magnusson Y, Hjalmarson A, et al. A novel polymorphism in the gene coding for the β₁-adrenergic receptor associated with survival in patients with heart failure[J]. Eur Heart J, 2000;21: 1853-1858.
20 Forleo C, Resta N, Sorrentino S, et al. Association of betaadrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy[J]. Am J Med, 2004; 117:451-458.
21 MuszkatM, Stein CM.Pharmacogenetics and response to betaadrenergic receptor antagonists in heart failure[J]. Clin Pharmacol Ther, 2005;77:123-126.
22 Xie HG, Dishy V, Sofowara G, et al. Arg389Gly β₁-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo[J]. Pharmacogenetics, 2001;11: 191-197.
23 Liggett SB.Molecular and genetic basis of beta2-adrenergic receptor function[J]. J Allergy Clin Immunol, 1999; 104: S42-S46.
24 Sandilands A, Yeo G, Brown MJ, et al. Functional responses of human beta1 adrenoceptors with defined haplotypes for the common 389R>G and 49S >G polymorphisms[J]. Pharmacogenetics, 2004;14: 343-349.
25 Terra SG, Pauly DF, Lee CR, et al. beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure[J]. Clin Pharmacol Ther, 2005;77: 127-137.
26 Liu J, Liu ZQ, Tan ZR, et al. Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol[J]. Clin Pharmacol Ther, 2003;74:372-379.
27 Liu J, Liu ZQ, Yu BN, et al. beta1-Adrenergic receptor polymorphisms influences the response to metoprolol monotherapy in patients with essential hypertension[J]. Clin Pharmacol Ther, 2006;80:23-32.
28 KobilK_a BK, Dixon RA, Frielle T, et al. cDNA for the human β₂-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor[J]. Proc Natl Acad Sci USA, 1987; 84:46-50.
29 Liggett SB, Freedman NJ, Schwinn DA, et al. Structural basis for receptor subtype-specific regulation revealed by a chimeric beta 3/beta 2-adrenergic receptor[J]. Proc Natl Acad Sci USA, 1993;90:3665-3669.
30 Ohe M, Munakata M, Hizawa N, et al. Beta 2 adrenergic receptor gene restriction fragment length polymorphism and bronchial asthma[J]. Thorax, 1995; 50:353-359.
31 Xie HG, Stein CM, Kim RB, et al. Frequency of functionally important β₂-adrenergic receptor polymorphisms varies markedly among African-American, Caucasian and Chinese individuals [J]. Pharmacogenetics, 1999;9:511-516.
32 Green SA, Turki J, Innis M, et al. Amino-terminal polymorphisms of the human β₂-adrenergic receptor impart distinct agonist-promoted regulatory properties[J]. Biochemistry, 1994; 33:9414-9419.
33 Chong LK, Chowdry J, Ghahramani P, et al. Influence of genetic polymorphisms in the β₂-adrenoceptor on desensitization in human lung mast cells[J]. Pharmacogenetics, 2000; 10:153-162.
34 Green SA, Cole G, Jacinto M, et al. A polymorphisms of the human β₂-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor[J]. J Biol Chem, 1993;268: 23116-23121.
35 Reihsaus E, Innis M, MacIntyre N, et al. Mutations in the gene encoding for the β₂-adrenergic receptor in normal and asthmatic subjects[J]. Am J Respir Cell Mol Biol, 1993;8: 334-339.
36 Turki J, Pak J, Green SA, et al. Genetic polymorphisms of the β₂-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype [J]. J Clin Invest, 1995;95: 1635-1641.
37 Martinez FD, Graves PE, Baldini M, et al. Association between genetic polymorphisms of the beta2-adrenoceptor and re-中国临床药理学与治疗学 2007 Jun;12(6) · 607 · sponse to albuterol in children with and without a history of wheezing[J]. J Clin Invest, 1997;100:3184-3188.
38 Liggett SB, Wagoner LE, Craft LL, et al. The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure[J]. J Clin Invest, 1998; 102: 1534-1539.
39 Scott MG, Swan C, Wheatley AP, et al. Identification of novel polymorphisms within the promoter region of the human β₂-adrenergic receptor gene[J]. Br J Pharmacol, 1999;126:841-844.
40 Mcgraw DW, Forbes SL, Kramer LA, et al. Polymorphisms of the 5' leader cistron of the human β₂-adrenergic receptor regulate receptor expression[J]. J Clin Invest, 1998;102:1927-1932.
41 Yamada K, Ishiyama-Shigemoto S, Ichikawa F, et al. Polymorphism in the 5'-leader cistron of the β₂-adrenergic receptor gene associated with obesity and type 2 diabetes[J]. J Clin Endocrinol Metab, 1999; 84:1754-1757.
42 Mitchell BD, Blangero J, Comuzzie AG, et al. A paired sibling analysis of the β₃-adrenergic receptor and obesity in Mexican Americans[J]. J Clin Invest, 1998; 101:584-587.
43 Kim-Motoyama H, Yasuda K, Yamaguchi T, et al. A mutation of the β₃-adrenergic receptor is associated with visceral obesity but decreased serum triglyceride[J]. Diabetologia, 1997; 40: 469-472.
44 Nagase T, Aoki A, Yamamoto M, et al. Lack of association between the Trp64Arg mutation in the β₃-adrenergic receptor gene and obesity in Japanese men: a longitudinal analy sis[J]. J Clin Endocrinol Metab, 1997; 82:1284-1287.
45 Thomas GN, Tomlinson B, Chan JC, et al. The Trp64Arg polymorphism of the beta3-adrenergic receptor gene and obesity in Chinese subjects with components of the metabolic syndrome [J]. Int J Obes RelatMetab Disord, 2000; 24:545-551.
46 Walston J, Silver K, Bogardus C, et al. Time of onset of noninsulin-dependent diabetes mellitus and genetic variation in the β₃-adrenergic-receptor gene[J]. N Engl J Med, 1995;333:343-347.
47 Garcia-Rubi E, Starling RD, Tchernof A, et al. Trp64Arg variant of the β₃-adrenoceptor and insulin resistance in obese postmenopausal women[J]. J Clin Endocrinol Metab, 1998; 83:4002-4005.
48 Mo W, Zhang GG, Yang TL, et al. The genetic polymorphisms of beta3-adrenergic receptor(AR) Trp64Arg and beta2-AR Gln27Glu are associated with obesity in Chinese male hypertensive patients[J]. Clin Chem Lab Med, 2007;45:493-498.

[1]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[2]	LIN Rongfang, ZHENG Weiwei, LIU Yiwei, LIN Cuihong, WANG Changlian, HUANG Pinfang. Correlation of infliximab related genetic polymorphism, serum trough concentration and efficacy in patients with Crohn's disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1000-1006.
[3]	LI Ling, ZHAO Huijia, CHEN Binyao, LIU Xiaohong, SUN Gongpeng, HAO Zhuowen, FAN Zhipeng, YUE Jiang, WU Jianguo, YE Qifa. Relevance of CYP2R1 genetic polymorphism and individual therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1053-1059.
[4]	CHEN Binyao, LI Ling, ZHAO Huijia, LIU Xiaohong, QI Zhenhua, SUN Gongpeng, HAO Zhuowen, FAN Zhipeng, DONG Li, YUE Jiang, YE Qifa. Relevance of CYP1B1 genetic polymorphism and individual therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1309-1316.
[5]	ZHOU Yuan, LU Xueling, ZHAO Jun, ZHANG Li, YANG Huanjie，WANG Ning. Polymorphism distribution of rs316019 of SLC22A2 in the Uygur population of Xinjiang [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(3): 287-293.
[6]	LIN Xiuxian, CHEN Dan, ZHAO Qing, CHEN Yao. Genetic research on the incidence of alcoholic liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(11): 1309-1314.
[7]	HU Jing, ZHU Jun-rong, YU Feng. Efficacy and safety of warfarin dosage algorithms in clinical application:A Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(3): 296-303.
[8]	MA Xiao-qin, XIN Hua-wen, LI Yuan-qi, HUANG Hui, ZHAO Li, YU Ai-rong, LI Wei-liang, WU Xiao-chun. Association of HGPRT activity and gene polymorphism with adverse reactions caused by azathioprine in kidney transplant recipients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(2): 182-187.
[9]	WU Ji-chu, OUYANG Ze-wei, LUO Can-xiang. Effect of ABCG2 genetic polymorphism on atorvastatin modifying serum lipids [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(8): 882-884.
[10]	OUYANG Cang-hong, XIE Juan. Study on the relationship between the MDR1 and CYP3A genetic polymorphisms and serum digoxin concentration in 111 patients with chronic heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(3): 291-296.
[11]	FENG Jing, WU Yue, RONG Pei-pei, SHEN Bing-zheng, ZHOU Ding-shan, SHI Cai, SONG Jin-chun. Progress on effects of pharmacogenetics of inosine triphosphate pyrophosphatase on improving the individualized thiopurine therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(12): 1435-1440.
[12]	HUANG Lu, YANG Guo-ping. Progress on influence of cytochrome P450 oxidoreductase polymorphisms on cytochrome P450 monoxyfenases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(7): 818-823.
[13]	GUO Yu, ZHOU Hong-hao, LIU Zhao-qian. MiRNA and interindividual difference in drug response [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(4): 443-448.
[14]	NING Wei, LIU Jie. Research advances in pharmacogenomics of levodopa [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(4): 455-460.
[15]	HUANG Qiong, ZHANG Liu-fu, CHENG Yan, SI Li, WEI Wei. Effect of β3-adrenergic receptor gene Trp64Arg polymorphism on uric acid levels in a Chinese male type 2 diabetes mellitus population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(3): 307-311.